Early Access — free while we kick the tires
EdgarHawk

Hyep Ivan

Chief Financial Officer

Officer
1 filing analyzed · 1 company · Latest 2025-10-08

Companies

Company Buys Sells Direction
Bicara Therapeutics Inc. BCAX 0 6 Net selling

Activity

October 2025
high
Sell
30,385 shares
$553,198
Significance 6/10

CFO Ivan Hyep sold 30,385 shares in 3 transactions for $553,198.15 at BCAX, reducing stake 17.3% during 46.5% rally

CFO Ivan Hyep executed 3 separate sales totaling 30,385 shares between October 6–8, 2025, at blended average price $18.21, realizing $553,198.15 and reducing his holdings from 175,740 to 145,355 shares. The sales occurred during a period of significant upward momentum (30-day change: +46.5%; 90-day change: +81.4%) and while the stock remains -28.5% below its 52-week high of $25.19. The timing of this substantial reduction warrants attention given that Bicara remains unprofitable (net income: $-27,388,000.00) and the company's $982,131,138.00 market cap is supported largely by recovery sentiment rather than demonstrated earnings. Without visibility into whether these sales are structured (e.g., 10b5-1 plan) or discretionary, the concurrent reduction in insider equity stake and the scale of the disposal merit investor scrutiny of underlying business conditions.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access